Abstract 4189: Evaluation of implantable cytokine factories in combination with checkpoint inhibitors for eradication of malignant pleural mesothelioma (MPM) tumors in mice with safe and predictable dosing in non-human primates
Amanda Nash(Rice University), Omid Veiseh(Rice University), Bertha Castillo(Rice University), Rahul A. Sheth(Massachusetts General Hospital), Bryan M. Burt(Baylor College of Medicine), Samira Aghlara-Fotovat(Integrated BioTherapeutics (United States)), José Oberholzer(University Hospital of Zurich), Andrea Hernández(Rice University), Sofia Ghani(TransUnion (United States)), Hee-Jin Jang(Baylor College of Medicine), Aarthi Pugazenthi(Baylor College of Medicine), Ira Joshi(TransUnion (United States)), Peter Rios(TransUnion (United States)), Weiyi Peng(University of Houston), Alexander Lu(Rice University), Hyun‐Sung Lee(Baylor College of Medicine), Ravi K. Ghanta(University of Virginia), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Douglas Isa(TransUnion (United States)), Chunyu Xu(University of Houston)
Cited by 1
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
|Clinical Cancer Research|2013|938
Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates
|Nature Materials|2015|895
Long-term glycemic control using polymer-encapsulated human stem cell–derived beta cells in immune-competent mice
|Nature Medicine|2016|708
Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates
|Nature Biotechnology|2016|551